QURE UNIQURE NV

uniQure Announces Change for its 2020 Annual General Meeting of Shareholders

uniQure Announces Change for its 2020 Annual General Meeting of Shareholders

~ Virtual Meeting Only by Live Audio Webcast – No Physical Meeting Location ~

LEXINGTON, Mass. and AMSTERDAM, June 15, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: QURE) announced today a change to the location and format of its 2020 Annual General Meeting of Shareholders (the “2020 Annual Meeting”). In light of the continuing coronavirus (COVID-19) pandemic and public health concerns, the location and format of the 2020 Annual Meeting will be conducted exclusively by remote communications, via the Internet.

The meeting will continue to be held on Wednesday, June 17, 2020, at 8:30 a.m. Eastern Standard Time/ 2:30 p.m. Central European Summer Time. Shareholders will not be able to attend the 2020 Annual Meeting in person and will not be able to vote their shares in real time, but shareholders of record as of the close of business on May 20, 2020, will be able to participate in the 2020 Annual Meeting through the virtual meeting platform.

To attend the 2020 Annual Meeting, shareholders may visit either the Investors and Newsroom section of the uniQure corporate website, or go directly to and enter the control number included on the notice, proxy card or voting instruction form previously distributed. Those without a control number may attend the 2020 Annual Meeting as guests by logging in to the same virtual meeting platform and following the instructions on the website for guest access. Unlike shareholders with control numbers, guests will not be able to ask questions at the 2020 Annual Meeting.

A replay of the webcast will be available via a link on the uniQure website in the Investors & Newsroom section under Corporate Governance.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and other severe genetic diseases.

uniQure Contacts:

FOR INVESTORS:  FOR MEDIA:
   
Maria E. CantorChiara RussoTom Malone   
Direct: 339-970-7536Direct: 617-306-9137Direct: 339-970-7558
Mobile:  617-680-9452Mobile: 617-306-9137Mobile:339-223-8541

EN
15/06/2020

Underlying

QUREUNIQURE NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on UNIQURE NV

 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Announces Second Quarter 2025 Financial Results and Highlights...

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress ~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company expects to present AMT-130 topline three-year data in September 2025 ~ ~ Presented case study from first participant treated with AMT-260 for refractory mesial temporal lobe epilepsy showing 92% seizure reduction with no serious adverse events through first five months of follow u...

July 29, 2025 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure to Announce Second Quarter 2025 Financial Results

uniQure to Announce Second Quarter 2025 Financial Results uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET LEXINGTON, Mass. and AMSTERDAM, July 22, 2025 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report second quarter 2025 financial results before market open on Tuesday, July 29, 2025. Management will then host a conference call at 8:30 a.m. ET. The event will be webcast under the Events & Presentations section of uniQure’s website at , and following th...

July 22, 2025 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and ...

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer ~ Proven biotech executive to lead commercialization of AMT-130 in Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Kylie O’Keefe as Chief Customer and Strategy Officer, effective June 6, 2025. In this role, Ms. O’Keefe will lead the development and execution of uniQure’s global commercialization strate...

June 11, 2025 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease ~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, June 02, 2025 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today provided a regulatory update on AMT-130, its investigational gene therapy for the treatment of Huntington’s disease. Following recent Type B meetings and...

June 2, 2025 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-2...

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) ~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to be presented today at Epilepsy Therapies & Diagnostics Development Symposium (ETDD) ~ LEXINGTON, Mass. and AMSTERDAM, May 29, 2025 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the presenta...

May 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch